Volition Advances Nu.Q® NETs Platform Toward Commercialization
VolitionRx Limited (NYSE AMERICAN: VNRX) has announced significant progress in the development and validation of its Nu.Q® NETs platform, a nucleosome quantification technology aimed at detecting diseases associated with neutrophil extracellular traps (NETosis). The company highlights consistent clinical data from multiple international studies showing that Nu.Q® H3.1 can accurately distinguish sepsis from non-infectious inflammation and is highly correlated with disease severity and patient outcomes. The platform has shown strong prognostic value, outperforming standard organ failure scores like APACHE II and SOFA in predicting mortality and organ failure. Volition's Chief Commercial Officer Gael Forterre noted ongoing discussions with major diagnostic companies to accelerate commercialization efforts within a $3.8 billion annualized addressable market. The company is preparing for the potential introduction of Nu.Q® NETs into hospitals, which could transform sepsis management by enabling personalized treatment strategies and improving patient survival rates.
Topics: biomarker epigenetics Nu.Q® NETs sepsis